SF2523 is a dual PI3K/BRD4 inhibitor generated from the TP series, which orthogonally hit PI3K and BRD4 to block expression, activation, and stabilization of Myc, leading to reduced tumor growth and metastasis in various preclinical models [158–160]. Here, MYC is linked to neoplasm.